A critical evaluation of Optilume® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in men
David C. Chen,Alice Thomson,Siyu Huang,Declan G. Murphy,Damien Bolton,Nathan Lawrentschuk,Marlon L. Perera
DOI: https://doi.org/10.21037/tau-23-578
2024-04-20
Translational Andrology and Urology
Abstract:David C. Chen 1,2,3,4 , Alice Thomson 1,4 , Siyu Huang 1,4 , Declan G. Murphy 1,4 , Damien Bolton 2,4 , Nathan Lawrentschuk 1,4,5 , Marlon L. Perera 1,2,4,5 1 Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 2 Department of Urology, Austin Health, Melbourne, Victoria, Australia; 3 Young Urological Researchers Organisation, Heidelberg, Victoria, Australia; 4 Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; 5 Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia Comment on: Kaplan SA, Moss J, Freedman S, et al . The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol 2023;210:500-9. Keywords: Prostate; benign prostate hyperplasia (BPH); Optilume ® BPH; minimally invasive surgical therapies (MIST) Submitted Nov 13, 2023. Accepted for publication Feb 08, 2024. Published online Apr 11, 2024. doi: 10.21037/tau-23-578 The prospective, double-blind, randomised, sham-controlled PINNACLE study assessed the safety and efficacy of Optilume ® BPH (Urotonic, Inc., Minneapolis, MN, USA) compared to a sham procedure in 148 men with symptomatic benign prostatic hyperplasia (BPH) as characterised by International Prostate Symptom Score (IPSS) of ≥13 and maximum urinary flow rate (Qmax) between 5–12 mL/s (1). Full inclusion and exclusion criteria are listed in Table 1 . IPSS, International Prostate Symptoms Score; Qmax, maximum urinary flow rate; PSA, prostate-specific antigen; UTI, urinary tract infection. Patients were randomised in a 2:1 ratio to receive Optilume BPH (n=100) or the sham therapy (n=48), stratified by centre and IPSS severity (≤19 or >19). Baseline characteristics were comparable across both groups. A maximum follow-up of 12 months was planned but was discontinued in patients who received additional BPH treatment if lower urinary tract symptoms (LUTS) continued. Patients randomised to the sham arm were permitted to cross over to receive treatment with Optilume BPH after the 3-month follow-up. The primary outcome was improvement in IPSS from baseline to 3 months in the sham arm against improvement from baseline to 1 year in the Optilume BPH arm. Optilume BPH combines anterior commissurotomy and simultaneous delivery of paclitaxel to prostatic adenoma in aim to create long-lasting channel patency in an ambulatory surgical setting. Prior to the procedure, prostatic urethral lengths are measured by transrectal ultrasound, with the intention to precisely select 1 of 4 drug-coated balloons (DCB) for each individual. Patients can receive general or local anaesthesia, in conjunction with oral sedation and local lubrication. Once the patient is draped and placed in a lithotomy position, cystoscopy is performed with a 20-Fr rigid cystoscope. First, a pre-dilatation balloon with a diameter of up to 90 Fr is inserted under direct vision and inflated for 5 minutes, and then removed. Then, a DCB catheter is inserted and inflated for 10 minutes, to deliver paclitaxel to the prostatic adenoma via the anterior commissurotomy. A 22–24-Fr 3 way in-dwelling catheter is placed, and continuous bladder irrigation is run for 30 minutes. The in-dwelling catheter remained in situ for 2 days postoperatively for both treatment arms. The trial reported positive efficacy results, meeting the primary outcome. Patients receiving Optilume BPH had a significantly greater IPSS improvement at 12 months (−11.5±7.8) compared to patients in the sham arm at 3 months (−8.0±8.3), however appeared insignificant when a 25% super-superiority margin (P=0.18) was assessed. Significantly more patients received an IPSS improvement ≥30% in the Optilume BPH arm compared to the sham arm [66/96 (68.8%) vs. 25/48 (52.1%), P=0.003]. Qmax improvement at 12 months compared to baseline was significantly more evident in patients receiving Optilume BPH over sham at 3 months (+9.7±10.1 vs. +5.5±7.4 mL/s, P=0.009). Between 3 and 6 months, one patient in the Optilume arm received BPH medication and one was lost to follow-up. In the control arm, 11 patients underwent a surgical procedure and one commenced BPH medication. Four patients from the Optilume BPH arm went on to have medical or surgical management of BPH, whereas 22—or almost half—of patients in the sham arm had either medical or surgical management of BPH during the follow-up window. Four patients (4%) had haematuria directly resulting from Optilume BPH that required further cystoscopic management. A false -Abstract Truncated-
urology & nephrology,andrology